arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

INTEGRA LIFESCIENCES HOLDINGS CORP

IART
$14.13 ▼ -0.69 (-4.69%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
73 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

INTEGRA LIFESCIENCES HOLDINGS CORP faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.1B
Dividend Yield —
Revenue Growth 2.3% ↗
Op. Margin 4.6% →
ROIC 1.0% ↘
FCF / Share $1.11 ↗
Trailing P/E 74.4x
Price / Book 1.0x
FCF Yield 7.8%
Debt / Equity 0.65
info Valuation on last close. End-of-day price, Nov 5, 2026.

73-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$411.18M
↑ +2.3% —
Net Income Profit after all expenses
$-4.62M
↑ +81.7% —
Operating Margin Operating profit as % of sales
4.6%
— -0.2% 8th
FCF / Share Free cash flow per share
$1.11
↑ +715.9% —
Long-Term Debt Long-term obligations
$697.50M
↓ -1.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
12
Returns
17
Financial Health ↑
40
Cash Quality ↓
24

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 73 quarters